Jacques-Emmanuel Galimard

Oct 2, 2023 | onlinelibrary.wiley.com | Jenny Byrne |Frédéric Baron |Arnon Nagler |Jacques-Emmanuel Galimard

CONFLICT OF INTEREST STATEMENT FB has received travel grants and/or speaker honoraria from Celgene, Abbvie, Novartis, Pfizer and Sanofi. The other authors declare that they have no relevant conflict of interest. REFERENCES 1, . Optimizing outcomes in secondary AML. Hematology Am Soc Hematol Educ Program. 2022; 2022: 23–29. 2, , , , , , et al. Survival improvement over time of 960 s-AML patients included in 13 EORTC-GIMEMA-HOVON trials. Cancer. 2020; 12(11): 3334. 3, , , , , , et al.